



**BlueCross BlueShield**  
of Vermont

An Independent Licensee of the Blue Cross and Blue Shield Association.

## Investigational Services and Procedures Corporate Medical Policy

File Name: Investigational Services and Procedures  
File Code: 10.01.VT204  
Origination: 09/2016  
Last Review: 04/01/2022  
Next Review: 07/01/2022  
Effective Date: 05/01/2022

### Description

Attachment I outlines current services and/or procedure(s) considered to be investigational by Blue Cross Blue Shield of Vermont (BCBSVT).

### Definition of Investigational

“Experimental or Investigational Services” means health care items or services that are either not generally accepted by informed health care providers in the United States as effective in treating a condition, illness, or diagnosis for which their use is proposed, or are not proven by medical or scientific evidence to be effective in treating a condition, illness, or diagnosis.

Technologies are assessed using the following criteria. Any technology that fails to meet ALL the following criteria is considered to be “Investigational”:

1. The technology must have final approval from the appropriate governmental regulatory bodies.
  - This criterion applies to drugs, biological products, devices and any other product or procedure that must have final approval to market from the U.S. Food and Drug Administration (FDA) or any other federal governmental body with authority to regulate the use of the technology.
  - Any approval that is granted as an interim step in the U.S. Food and Drug Administration’s or any other federal governmental body’s regulatory process is not sufficient.
  - The indications for which the technology is approved need not be the same as those which the (BCBSVT) Medical Policy Committee is evaluating.

2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes.
  - The evidence should consist of well-designed and well-conducted investigations published in peer-reviewed journals. The quality of the body of studies and the consistency of the results are considered in evaluating the evidence.
  - The evidence should demonstrate that the technology can measure or alter the physiological changes related to a disease, injury, illness, or condition. In addition, there should be evidence, or a convincing argument based on established medical facts that such measurement or alteration affects health outcomes.
3. The technology must improve the net health outcome.
  - The technology's beneficial effects on health outcomes should outweigh any harmful effects on health outcomes.
4. The technology must be as beneficial as any established alternatives.
  - The technology should improve the net health outcome as much as, or more than, established alternatives.
5. The improvement must be attainable outside the investigational settings.
  - When used under the usual conditions of medical practice, the technology should be reasonably expected to satisfy Criteria #3 and #4.

In reviewing the above criteria, the BCBSVT Medical Policy Committee will consider physician specialty society recommendations, the view of prudent medical practitioners practicing in relevant clinical areas and any other relevant factors.

## Policy

The following is a list of current services and/or procedure(s) which are considered investigational.

## Coding Information

### [Attachment I](#)

### Policy Implementation/Update information

06/2020	Policy new Format
10/2020	Coding Updates effective 10/01/2020 Medical Policy: Added codes: 0097U, 0107U, 82239, 82272, 82274, 82542, 82656, 82710, 82715, 82725, 83520, 83630, 83986, 83993, 84311, 87045, 87046, 87075, 87102, 87177, 87209, 87328, 87329, 87336, 89160, 89161, 89240 ARE CONSIDERED INVESTIGATIONAL WITH THE FOLLOWING DIAGNOSES CODES: A04.8, A04.9,

	K58.0, K58.1, K58.2, K58.8, K58.9, K59.8, K63.9, K90.89. Coding Updates effective 10/01/2020 via Adaptive Maintenance Cycle: Added codes: 0016M, 0203U, 0204U, 0205U, 0206U, 0207U, 0208U, 0209U, 0211U, 0216U, 0217U, 0218U, 0219U, 0220U, 0225U, K1006, K1007, K1010, K1011, K1012, Q4249, Q4250, Q4254, Q4255.
01/2021	Coding Updates effective 01/01/2021 Adaptive Maintenance Cycle: Changed effective date to 01/01/2021 Removed Codes 38230, 83993, 90694 Updated Codes 82172 & 84181 to Investigational for All diagnoses Updated Codes 64910, 64911, 64912, 64913 as Investigational with dx codes C61, N52.0-N52.9 Added codes 0227U, 0228U, 0229U, 0620T, 0621T, 0622T, 0623T, 0624T, 0625T, 0626T, 0627T, 0628T, 0629T, 0630T, 0631T, 0632T, 0633T, 0634T, 0635T, 0636T, 0637T, 0638T, 0639T, 22869, 22870, 30468, 55880, 57465, 81514, 92229, C1825, C9771, C9772, C9773, C9774, C9775 Deleted codes 0400T, 0401T Removed codes 38206, 38230, 38241 codes require PA
04/2021	Coding Updates effective 04/01/2021 Adaptive Maintenance Cycle: Added codes: C9776, C9777, J3490, K1016, K1017, K1018, K1019, K1020, S1091, 0242U, 0243U, 0244U, 0247U. Removed codes: K1010, K1011, K1012, 64451, 78803, 78830, 78831, 78832, 78835
05/2021	Coding Update effective 05/01/2021: Added codes 81518, 0045U, 0153U.
07/2021	Coding Updates effective 07/01/2021: 0248U, 0249U, 0250U, 0251U, 0252U, 0253U, 0640T, 0641T, 0642T, 0643T, 0645T, 0646T, 0647T, 0648T, 0649T, 0652T, 0653T, 0654T, 0655T, 0656T, 0657T, 0658T, 0659T, 0660T, 0661T, 0664T, 0665T, 0666T, 0667T, 0668T, 0669T, 0670T, A9593, A9594, G0327, 58674, 90626, 90627, 90671, 90677, 90758, C1761
08/2021	Coding Updates effective 08/01/2021: Added codes E1700, E1701, E1702
09/2021	Coding update effective 09/01/2021: Removed code 53854
10/2021	Coding update effective 10/01/2021: Added Codes 0255U, 0258U, 0259U, 0260U, 0261U, 0262U, 0263U, 0264U, 0266U, 0267U, 0279U, 0280U, 0281U, 0282U, 0283U, 0284U, 0018M, Deleted code 0139U. Revised 0051U descriptor. Added HCPCS Codes: C1831, C9780, K1023, K1024, K1025, K1026, Q4251, Q4252, Q4253
11/2021	Coding update effective 11/01/2021 (To Align Corporate Bioengineered Skin Medical Policy Table): Added codes C9354, C9356, C9358, C9360, C9363, C9364, Q4103, Q4104, Q4110, Q4111, Q4112, Q4113, Q4115, Q4117, Q4118, Q4121, Q4123, Q4124, Q4125, Q4126, Q4127, Q4130, Q4134, Q4135, Q4136, Q4141, Q4142, Q4143, Q4146, Q4147, Q4149, Q4152, Q4158, Q4161, Q4164, Q4165, Q4166, Q4167, Q4179, Q4182, Q4193, Q4196, Q4200, Q4202, Q4203, Q4222. Removed codes: Q4185, Q4189, Q4192, Q4249, Q4250, Q4254, Q4255.
12/2021	Coding update effective 12/01/2021: Added code G9143
12/2021	Coding Update Effective 01/01/2022 (Adaptive Maintenance Cycle): Deleted the following codes: 0548T, 0549T, 0550T, 0551T, C9752, C9753, 95943, 0208U Codes Added: 33370, 42975, 43497, 53451, 53452, 53453, 53454, 61736, 61737, 64628, 64629, 81560, 90759. Added codes PLA: 0285U, 0288U, 0289U, 0290U, 0291U, 0292U, 0293U, 0294U, 0295U, 0296U, 0297U, 0298U, 0299U, 0300U, 0303U, 0304U, 0305U. Added codes CAT III: 0672T, 0673T, 0674T, 0675T, 0676T, 0677T, 0678T, 0679T, 0680T, 0681T, 0682T, 0683T, 0684T, 0685T, 0686T, 0687T, 0688T,

	0689T, 0690T, 0691T, 0693T, 0694T, 0695T, 0696T, 0697T, 0698T, 0700T, 0701T, 0702T, 0703T, 0704T, 0705T, 0706T, 0707T, 0708T, 0709T, 0710T, 0711T, 0712T, 0713T. Added the following HCPCS Codes: A2001, A2002, A2004, A2005, A2006, A2007, A2008, A2009, A2010, C1832, C1833, G0465, Q4199. Removed codes: 0030U, 0032U, 0033U, 0173U, 0175U, 90677.
04/2022	Coding Update Effective 04/01/2022 (Adaptive Maintenance Cycle): A2003 deleted code never became effective 01/01/2021. (0)097U deleted. Added codes: 0306U, 0307U, 0308U, 0309U, 0310U, 0311U, 0312U, 0313U, 0314U, 0315U, 0316U, 0317U, 0318U, 0319U, 0320U, 0321U, 0322U. A2013, A9291, C9781, K1028, K1029, K1030, K1031, K1032, K1033. Removed code J3490 per Ketamine Medical Policy effective 04/01/2022.
05/2022	Coding Update Effective 05/01/2022 (Investigational Medical Policy Reconciliation): Codes removed: A4641, A4642, A9500, A9502, A9520, A9541, A9568, A9572, A9582 may be eligible for benefit approved by AIM or BCBSVT. Codes removed: J9035, 15788, 15789, 15792, 15793, 17000, 17003, 17004, 30520, 17106, 17107, 17108, 82656, 83630, 90677 effective: 01/01/2022), 97032 may be eligible for services based on current standards of care. Codes removed: G0259, L8603*, L8605*, L8606*, L8684, S8080, 0026U, 0097U, 0107U, 0278T, 15824, 15826, 30130, 30140, 31626, 34701, 34702, 34703, 34704, 34705, 34706, 34707, 34708, 36012, 37241, 38242, 43201, 43210, 43212, 43257, 51715, 64590, 64595, 64632, 64640, 64716, 64722, 64771, 64772, 64910, 64911, 64912, 64913, 76940, 78195, 78800, 78801, 78802, 78804, 82239, 82272, 82274, 82397, 82542, 82652, 82710, 82715, 82725, 83520, 83698, 83986, 84311, 86141, 86304, 87045, 87046, 87075, 87102, 87177, 87209, 87328, 87329, 87336, 89160, 89240, 92229, 93895, 95812, 95813, 95816, 95819, 95921, 95922, 95923, 95924, 96904 codes require prior approval. Removed codes: E0748, E0749, J3490, L8680, L8681, L8682, L8683, L8685, L8686, L8687, L8688, L8689, Q4168, Q4185, Q4189, Q4192, S3852, 0029U, 0156U, 0173U, 0175U, 0278U, 0394T, 15780, 15781, 15782, 15783, 20974, 20975, 61885, 61886, 64553, 64568, 64569, 64570, 67900, 75571, 81226, 81291, 81313, 81400, 81401, 81403, 81406, 81407, 81415, 81416, 81417, 81439, 81490, 81493, 81500, 81503, 81504, 81535, 81536, 81538, 81540, 81595, 95980, 95981, 95982 codes always required prior approval. Changed the following codes to be investigational for all diagnoses: A9584, E0740, E0761, E0769, G0166, G0295, G0329, G9147, S3722, 0003U, 0101T, 0102T, 0207T, 0278T, 0330T, 0332T, 0338T, 0339T, 0397T, 0421T, 0424T, 0425T, 0426T, 0441T, 0563T, 28890, 33548, 43206, 43252, 43284, 43285, 43647, 43648, 43881, 43882, 46707, 47371, 47381, 47383, 62263, 62264, 64505, 77085, 77086, 82523, 83006, 83695, 84080, 85384, 86352, 88375, 95957, 97610, 98922. Added new codes: C1825, C9359, C9362, E0746, G9143, S8130, S8131, 0651T, 64575 investigational for all diagnoses. Removed codes: G0281, G0282, V5095, 90876, 97014 codes are considered non-covered. Removed code S2080 code considered not medically necessary. Removed codes 31627 & 57465 not medically necessary per payment policy CPP_04. Added codes to as investigation but have been investigational per applicable medical policy: E0762, E0764, M0076, P9020, S8040, 0232T, 0355T, 41512, 64585, 83937, 91111, 92548, 92145, 92572, 92576, 93701, 95803, 96000, 96001, 96002, 96003, 96004, 97799. Codes deleted: A9599, C9750, 0355T, 0399T, 0406T, 0407T, 30660, 30661, 61632, 98922.

## Eligible Providers

Qualified healthcare professionals practicing within the scope of their license(s).

### Approved by BCBSVT Medical Directors

### Date Approved

Joshua Plavin, MD, MPH, MBA  
Chief Medical Officer

Tom Weigel, MD, MBA  
Senior Medical Director

## Attachment I

CPT®/HCPCS Code	CPT®/HCPCS Code Description	Instructions
A2001	InnovaMatrix AC, per sq cm	Investigational
A2002	Mirragen Advanced Wound Matrix, per sq cm	Investigational
A2004	XCelliStem, per sq cm	Investigational
A2005	Microlyte Matrix, per sq cm	Investigational
A2006	NovoSorb SynPath dermal matrix, per sq cm	Investigational
A2007	Restrata, per sq cm	Investigational
A2008	TheraGenesis, per sq cm	Investigational
A2009	Symphony, per sq cm	Investigational
A2010	Apis, per sq cm	Investigational
A2013	Innovamatrix FS, per sq cm	Investigational
A4563	Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each	Investigational
A4575	Topical hyperbaric oxygen chamber, disposable	Investigational
A9291	Prescription digital behavioral therapy, FDA-cleared, per course of treatment	Investigational
A9507	Indium In-111 capromab pendetide, diagnostic, per study dose, up to 10 millicuries	Investigational
A9584	Iodine I-123 ioflupane, diagnostic, per study dose, up to 5 mCi	Investigational
A9586	Florbetapir F18, diagnostic, per study dose, up to 10 mCi	Investigational
A9593	Gallium Ga-68 PSMA-11, diagnostic, (UCSF), 1 mCi	Investigational

<b>A9594</b>	Gallium Ga-68 PSMA-11, diagnostic, (UCLA), 1 mCi	Investigational
<b>C1734</b>	Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable)	Investigational
<b>C1761</b>	Catheter, transluminal intravascular lithotripsy, coronary	Investigational
<b>C1821</b>	Interspinous process distraction device (implantable)	Investigational
<b>C1823</b>	Generator, neurostimulator (implantable), nonrechargeable, with transvenous sensing and stimulation leads	Investigational
<b>C1825</b>	Generator, neurostimulator (implantable), nonrechargeable with carotid sinus baroreceptor stimulation lead(s)	Investigational
<b>C1831</b>	Personalized, anterior and lateral interbody cage (implantable)	Investigational
<b>C1832</b>	Autograft suspension, including cell processing and application, and all system components	Investigational
<b>C1833</b>	Monitor, cardiac, including intracardiac lead and all system components (implantable)	Investigational
<b>C1841</b>	Retinal prosthesis, includes all internal and external components	Investigational
<b>C2596</b>	Probe, image guided, robotic, waterjet ablation	Investigational
<b>C2614</b>	Probe, percutaneous lumbar discectomy	Investigational
<b>C8937</b>	Computer-aided detection, including computer algorithm analysis of breast MRI image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)	Investigational
<b>C9354</b>	Acellular pericardial tissue matrix of nonhuman origin (Veritas), per sq cm	Investigational
<b>C9356</b>	Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (TenoGlide Tendon Protector Sheet), per sq cm	Investigational

<b>C9358</b>	Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm	Investigational
<b>C9359</b>	Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Putty, Integra OS Osteoconductive Scaffold Putty), per 0.5 cc	Investigational
<b>C9360</b>	Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm	Investigational
<b>C9362</b>	Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Strip), per 0.5 cc	Investigational
<b>C9363</b>	Skin substitute (Integra Meshed Bilayer Wound Matrix), per sq cm	Investigational
<b>C9364</b>	Porcine implant, Permacol, per sq cm	Investigational
<b>C9751</b>	Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)	Investigational

<b>C9758</b>	Blind procedure for NYHA Class III/IV heart failure; transcatheter implantation of interatrial shunt including right heart catheterization, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	Investigational
<b>C9759</b>	Transcatheter intraoperative blood vessel microinfusion(s) (e.g., intraluminal, vascular wall and/or perivascular) therapy, any vessel, including radiological supervision and interpretation, when performed	Investigational
<b>C9760</b>	Nonrandomized, nonblinded procedure for NYHA Class II, III, IV heart failure; transcatheter implantation of interatrial shunt, including right and left heart catheterization, transeptal puncture, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	Investigational
<b>C9762</b>	Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with strain imaging	Investigational
<b>C9763</b>	Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with stress imaging	Investigational

<b>C9764</b>	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9765</b>	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9766</b>	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9767</b>	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9771</b>	Nasal/sinus endoscopy, cryoablation nasal tissue(s) and/or nerve(s), unilateral or bilateral	Investigational
<b>C9772</b>	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies), with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9773</b>	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed	Investigational

<b>C9774</b>	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9775</b>	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9776</b>	Intraoperative near-infrared fluorescence imaging of major extra-hepatic bile duct(s) (e.g., cystic duct, common bile duct and common hepatic duct) with intravenous administration of indocyanine green (ICG) (list separately in addition to code for primary procedure)	Investigational
<b>C9777</b>	Esophageal mucosal integrity testing by electrical impedance, transoral, includes esophagoscopy or esophagogastroduodenoscopy	Investigational
<b>C9780</b>	Insertion of central venous catheter through central venous occlusion via inferior and superior approaches (e.g., inside-out technique), including imaging guidance	Investigational
<b>C9781</b>	Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed	Investigational
<b>E0218</b>	Fluid circulating cold pad with pump, any type	Investigational
<b>E0236</b>	Pump for water circulating pad	Investigational
<b>E0740</b>	Nonimplanted pelvic floor electrical stimulator, complete system	Investigational

<b>E0746</b>	Electromyography (EMG), biofeedback device	Investigational
<b>E0761</b>	Nonthermal pulsed high frequency radiowaves, high peak power electromagnetic energy treatment device	Investigational
<b>E0762</b>	Transcutaneous electrical joint stimulation device system, includes all accessories	Investigational
<b>E0764</b>	Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program	Investigational
<b>E0769</b>	Electrical stimulation or electromagnetic wound treatment device, not otherwise classified	Investigational
<b>E0770</b>	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified	Investigational
<b>E1700</b>	Jaw motion rehabilitation system	Investigational
<b>E1701</b>	Replacement cushions for jaw motion rehabilitation system, package of 6	Investigational
<b>E1702</b>	Replacement measuring scales for jaw motion rehabilitation system, package of 200	Investigational
<b>G0166</b>	External counterpulsation, per treatment session	Investigational
<b>G0255</b>	Current perception threshold/sensory nerve conduction test, (SNCT) per limb, any nerve	Investigational
<b>G0276</b>	Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial	Investigational
<b>G0295</b>	Electromagnetic therapy, to one or more areas, for wound care other than described in G0329 or for other uses	Investigational

<b>G0327</b>	Colorectal cancer screening; blood-based biomarker	Investigational
<b>G0329</b>	Electromagnetic therapy, to one or more areas for chronic Stage III and Stage IV pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care as part of a therapy plan of care	Investigational
<b>G0465</b>	Autologous platelet rich plasma (PRP) for diabetic chronic wounds/ulcers, using an FDA-cleared device (includes administration, dressings, phlebotomy, centrifugation, and all other preparatory procedures, per treatment)	Investigational
<b>G2000</b>	Blinded administration of convulsive therapy procedure, either electroconvulsive therapy (ECT, current covered gold standard) or magnetic seizure therapy (MST, noncovered experimental therapy), performed in an approved IDE-based clinical trial, per treatment session	Investigational
<b>G2170</b>	Percutaneous arteriovenous fistula creation (AVF), direct, any site, by tissue approximation using thermal resistance energy, and secondary procedures to redirect blood flow (e.g., transluminal balloon angioplasty, coil embolization) when performed, and includes all imaging and radiologic guidance, supervision and interpretation, when performed	Investigational

<b>G2171</b>	Percutaneous arteriovenous fistula creation (AVF), direct, any site, using magnetic-guided arterial and venous catheters and radiofrequency energy, including flow-directing procedures (e.g., vascular coil embolization with radiologic supervision and interpretation, when performed) and fistulogram(s), angiography, venography, and/or ultrasound, with radiologic supervision and interpretation, when performed	Investigational
<b>G9143</b>	Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)	Investigational
<b>G9147</b>	Outpatient Intravenous Insulin Treatment (OIVIT) either pulsatile or continuous, by any means, guided by the results of measurements for: respiratory quotient; and/or, urine urea nitrogen (UUN); and/or, arterial, venous or capillary glucose; and/or potassium concentration	Investigational
<b>K1001</b>	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type	Investigational
<b>K1002</b>	Cranial electrotherapy stimulation (CES) system, includes all supplies and accessories, any type	Investigational
<b>K1004</b>	Low frequency ultrasonic diathermy treatment device for home use, includes all components and accessories	Investigational
<b>K1006</b>	Suction pump, home model, portable or stationary, electric, any type, for use with external urine management system	Investigational

<b>K1007</b>	Bilateral hip, knee, ankle, foot (HKAFO) device, powered, includes pelvic component, single or double upright(s), knee joints any type, with or without ankle joints any type, includes all components and accessories, motors, microprocessors, sensors	Investigational
<b>K1016</b>	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve	Investigational
<b>K1017</b>	Monthly supplies for use of device coded at K1016	Investigational
<b>K1018</b>	External upper limb tremor stimulator of the peripheral nerves of the wrist	Investigational
<b>K1019</b>	Monthly supplies for use of device coded at K1018	Investigational
<b>K1020</b>	Noninvasive vagus nerve stimulator	Investigational
<b>K1023</b>	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm	Investigational
<b>K1024</b>	Nonpneumatic compression controller with sequential calibrated gradient pressure	Investigational
<b>K1025</b>	Nonpneumatic sequential compression garment, full arm	Investigational
<b>K1026</b>	Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical	Investigational
<b>K1028</b>	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle for the reduction of snoring and obstructive sleep apnea, controlled by phone application	Investigational
<b>K1029</b>	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply	Investigational

<b>K1030</b>	External recharging system for battery (internal) for use with implanted cardiac contractility modulation generator, replacement only	Investigational
<b>K1031</b>	Nonpneumatic compression controller without calibrated gradient pressure	Investigational
<b>K1032</b>	Nonpneumatic sequential compression garment, full leg	Investigational
<b>K1033</b>	Nonpneumatic sequential compression garment, half leg	Investigational
<b>L8608</b>	Miscellaneous external component, supply or accessory for use with the Argus II Retinal Prosthesis System	Investigational
<b>M0076</b>	Prolotherapy	Investigational
<b>P9020</b>	Platelet rich plasma, each unit	Investigational
<b>Q4103</b>	Oasis burn matrix, per sq cm	Investigational
<b>Q4104</b>	Integra bilayer matrix wound dressing (BMWD), per sq cm	Investigational
<b>Q4110</b>	PriMatrix, per sq cm	Investigational
<b>Q4111</b>	GammaGraft, per sq cm	Investigational
<b>Q4112</b>	Cymetra, injectable, 1 cc	Investigational
<b>Q4113</b>	GRAFTJACKET XPRESS, injectable, 1 cc	Investigational
<b>Q4115</b>	AlloSkin, per sq cm	Investigational
<b>Q4117</b>	HYALOMATRIX, per sq cm	Investigational
<b>Q4118</b>	MatriStem micromatrix, 1 mg	Investigational
<b>Q4121</b>	TheraSkin, per sq cm	Investigational
<b>Q4123</b>	AlloSkin RT, per sq cm	Investigational
<b>Q4124</b>	OASIS ultra tri-layer wound matrix, per sq cm	Investigational
<b>Q4125</b>	ArthroFlex, per sq cm	Investigational
<b>Q4126</b>	MemoDerm, DermaSpan, TranZgraft or InteguPly, per sq cm	Investigational
<b>Q4127</b>	Talymed, per sq cm	Investigational
<b>Q4130</b>	Strattice TM, per sq cm	Investigational
<b>Q4134</b>	HMatrix, per sq cm	Investigational
<b>Q4135</b>	Mediskin, per sq cm	Investigational
<b>Q4136</b>	E-Z Derm, per sq cm	Investigational
<b>Q4141</b>	AlloSkin AC, per sq cm	Investigational
<b>Q4142</b>	XCM biologic tissue matrix, per sq cm	Investigational
<b>Q4143</b>	Repriza, per sq cm	Investigational
<b>Q4146</b>	Tensix, per sq cm	Investigational

<b>Q4147</b>	Architect, Architect PX, or Architect FX, extracellular matrix, per sq cm	Investigational
<b>Q4149</b>	Excellagen, 0.1 cc	Investigational
<b>Q4152</b>	DermaPure, per sq cm	Investigational
<b>Q4158</b>	Kerecis Omega3, per sq cm	Investigational
<b>Q4161</b>	bio-ConneKt wound matrix, per sq cm	Investigational
<b>Q4164</b>	Helicoll, per sq cm	Investigational
<b>Q4165</b>	Keramatrix or Kerasorb, per sq cm	Investigational
<b>Q4166</b>	Cytal, per sq cm	Investigational
<b>Q4167</b>	Truskin, per sq cm	Investigational
<b>Q4179</b>	FlowerDerm, per sq cm	Investigational
<b>Q4182</b>	Transcyte, per sq cm	Investigational
<b>Q4193</b>	Coll-e-Derm, per sq cm	Investigational
<b>Q4196</b>	PuraPly AM, per sq cm	Investigational
<b>Q4199</b>	Cygnus matrix, per sq cm	Investigational
<b>Q4200</b>	SkinTE, per sq cm	Investigational
<b>Q4202</b>	Keroxx (2.5 g/cc), 1 cc	Investigational
<b>Q4203</b>	Derma-Gide, per sq cm	Investigational
<b>Q4222</b>	ProgenaMatrix, per sq cm	Investigational
<b>Q4251</b>	Vim, per sq cm	Investigational
<b>Q4252</b>	Vendaje, per sq cm	Investigational
<b>Q4253</b>	Zenith Amniotic Membrane, per sq cm	Investigational
<b>Q9982</b>	Flutemetamol F18, diagnostic, per study dose, up to 5 mCi	Investigational
<b>Q9983</b>	Florbetaben F18, diagnostic, per study dose, up to 8.1 mCi	Investigational
<b>S1091</b>	Stent, noncoronary, temporary, with delivery system (Propel)	Investigational
<b>S2117</b>	Arthroereisis, subtalar	Investigational
<b>S2230</b>	Implantation of magnetic component of semi-implantable hearing device on ossicles in middle ear	Investigational
<b>S2348</b>	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar	Investigational
<b>S3722</b>	Dose optimization by area under the curve (AUC) analysis, for infusional 5-fluorouracil	Investigational
<b>S8040</b>	Topographic brain mapping	Investigational

<b>S8130</b>	Interferential current stimulator, 2 channel	Investigational
<b>S8131</b>	Interferential current stimulator, 4 channel	Investigational
<b>S8930</b>	Electrical stimulation of auricular acupuncture points; each 15 minutes of personal one-on-one contact with patient	Investigational
<b>S9090</b>	Vertebral axial decompression, per session	Investigational
<b>V2799</b>	Vision item or service, miscellaneous	Investigational
<b>0003U</b>	Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score	Investigational
<b>0004M</b>	Scoliosis, DNA analysis of 53 single nucleotide polymorphisms (SNPs), using saliva, prognostic algorithm reported as a risk score	Investigational
<b>0011M</b>	Oncology, prostate cancer, mRNA expression assay of 12 genes (10 content and 2 housekeeping), RT-PCR test utilizing blood plasma and urine, algorithms to predict high-grade prostate cancer risk	Investigational
<b>0014M</b>	Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years	Investigational
<b>0016M</b>	Oncology (bladder), mRNA, microarray gene expression profiling of 209 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as molecular subtype (luminal, luminal infiltrated, basal, basal claudin-low, neuroendocrine-like)	Investigational

<b>0018M</b>	Transplantation medicine (allograft rejection, renal), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score	Investigational
<b>0024U</b>	Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative	Investigational
<b>0025U</b>	Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative	Investigational
<b>0031U</b>	CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)	Investigational
<b>0034U</b>	TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5)	Investigational
<b>0035U</b>	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative	Investigational
<b>0037U</b>	Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	Investigational
<b>0038U</b>	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative	Investigational
<b>0039U</b>	Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity	Investigational
<b>0041U</b>	Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM	Investigational

<b>0042U</b>	Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG	Investigational
<b>0043U</b>	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM	Investigational
<b>0044U</b>	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG	Investigational
<b>0045U</b>	Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score	Investigational
<b>0047U</b>	Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score	Investigational
<b>0048U</b>	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)	Investigational
<b>0050U</b>	Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements	Investigational

<b>0051U</b>	Prescription drug monitoring, evaluation of drugs present by liquid chromatography tandem mass spectrometry (LC-MS/MS), urine or blood, 31 drug panel, reported as quantitative results, detected or not detected, per date of service	Investigational
<b>0052U</b>	Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation	Investigational
<b>0053U</b>	Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade	Investigational
<b>0054U</b>	Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service	Investigational
<b>0055U</b>	Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma	Investigational
<b>0058U</b>	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative	Investigational
<b>0059U</b>	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative	Investigational
<b>0060U</b>	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood	Investigational

<b>0061U</b>	Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis	Investigational
<b>0062U</b>	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score	Investigational
<b>0067U</b>	Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score	Investigational
<b>0069U</b>	Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score	Investigational
<b>0075T</b>	Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; initial vessel	Investigational
<b>0076T</b>	Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; each additional vessel (List separately in addition to code for primary procedure)	Investigational

<b>0078U</b>	Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder	Investigational
<b>0080U</b>	Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy	Investigational
<b>0082U</b>	Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service	Investigational
<b>0083U</b>	Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations	Investigational
<b>0084U</b>	Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens	Investigational
<b>0087U</b>	Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score	Investigational

<b>0088U</b>	Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection	Investigational
<b>0089U</b>	Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es)	Investigational
<b>0090U</b>	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)	Investigational
<b>0091U</b>	Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result	Investigational
<b>0092U</b>	Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy	Investigational
<b>0095U</b>	Inflammation (eosinophilic esophagitis), ELISA analysis of eotaxin-3 (CCL26 [C-C motif chemokine ligand 26]) and major basic protein (PRG2 [proteoglycan 2, pro eosinophil major basic protein]), specimen obtained by swallowed nylon string, algorithm reported as predictive probability index for active eosinophilic esophagitis	Investigational
<b>0100T</b>	Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy	Investigational
<b>0101T</b>	Extracorporeal shock wave involving musculoskeletal system, not otherwise specified	Investigational

<p><b>0101U</b></p>	<p>Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])</p>	<p>Investigational</p>
<p><b>0102T</b></p>	<p>Extracorporeal shock wave performed by a physician, requiring anesthesia other than local, and involving the lateral humeral epicondyle</p>	<p>Investigational</p>
<p><b>0102U</b></p>	<p>Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])</p>	<p>Investigational</p>
<p><b>0103U</b></p>	<p>Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], EPCAM [deletion/duplication only])</p>	<p>Investigational</p>

<b>0105U</b>	Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD)	Investigational
<b>0106T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation	Investigational
<b>0106U</b>	Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (13C) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13CO2 excretion	Investigational
<b>0107T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation	Investigational
<b>0108T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia	Investigational
<b>0108U</b>	Gastroenterology (Barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer	Investigational

<b>0109T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia	Investigational
<b>0110T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation	Investigational
<b>0110U</b>	Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected	Investigational
<b>0113U</b>	Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score	Investigational
<b>0114U</b>	Gastroenterology (Barrett's esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett's esophagus	Investigational
<b>0116U</b>	Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications	Investigational

<b>0117U</b>	Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain	Investigational
<b>0118U</b>	Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA	Investigational
<b>0119U</b>	Cardiology, ceramides by liquid chromatography-tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events	Investigational
<b>0120U</b>	Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter	Investigational
<b>0121U</b>	Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood	Investigational
<b>0122U</b>	Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood	Investigational
<b>0123U</b>	Mechanical fragility, RBC, shear stress and spectral analysis profiling	Investigational

<b>0129U</b>	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication analysis panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53)	Investigational
<b>0130U</b>	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure)	Investigational
<b>0131U</b>	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure)	Investigational
<b>0132U</b>	Hereditary ovarian cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure)	Investigational
<b>0133U</b>	Hereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure)	Investigational
<b>0134U</b>	Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure)	Investigational

<b>0135U</b>	Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure)	Investigational
<b>0136U</b>	ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure)	Investigational
<b>0137U</b>	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)	Investigational
<b>0138U</b>	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)	Investigational
<b>0152U</b>	Infectious disease (bacteria, fungi, parasites, and DNA viruses), microbial cell-free DNA, plasma, untargeted next-generation sequencing, report for significant positive pathogens	Investigational
<b>0153U</b>	Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement	Investigational
<b>0163T</b>	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), each additional interspace, lumbar (List separately in addition to code for primary procedure)	Investigational

<b>0163U</b>	Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas	Investigational
<b>0164T</b>	Removal of total disc arthroplasty, (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)	Investigational
<b>0164U</b>	Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results	Investigational
<b>0165T</b>	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)	Investigational
<b>0165U</b>	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and probability of peanut allergy	Investigational
<b>0166U</b>	Liver disease, 10 biochemical assays (a2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation	Investigational

<b>0169U</b>	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants	Investigational
<b>0170U</b>	Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis	Investigational
<b>0171U</b>	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence	Investigational
<b>0174U</b>	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents	Investigational
<b>0176U</b>	Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA)	Investigational
<b>0178U</b>	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction	Investigational
<b>0179U</b>	Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s)	Investigational

<b>0180U</b>	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons	Investigational
<b>0181U</b>	Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1	Investigational
<b>0182U</b>	Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10	Investigational
<b>0183U</b>	Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19	Investigational
<b>0184U</b>	Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2	Investigational
<b>0185U</b>	Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4	Investigational
<b>0186U</b>	Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2	Investigational
<b>0187U</b>	Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2	Investigational
<b>0188U</b>	Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4	Investigational
<b>0189U</b>	Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2	Investigational

<b>0190U</b>	Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3	Investigational
<b>0191U</b>	Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6	Investigational
<b>0192U</b>	Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9	Investigational
<b>0193U</b>	Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26	Investigational
<b>0194U</b>	Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endopeptidase [Kell blood group]) exon 8	Investigational
<b>0195U</b>	KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13)	Investigational
<b>0196U</b>	Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3	Investigational
<b>0197U</b>	Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1	Investigational
<b>0198U</b>	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5	Investigational
<b>0199U</b>	Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12	Investigational

<b>0200U</b>	Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3	Investigational
<b>0201U</b>	Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2	Investigational
<b>0202T</b>	Posterior vertebral joint(s) arthroplasty (eg, facet joint[s] replacement), including facetectomy, laminectomy, foraminotomy, and vertebral column fixation, injection of bone cement, when performed, including fluoroscopy, single level, lumbar spine	Investigational
<b>0202U</b>	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	Investigational
<b>0203U</b>	Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness	Investigational
<b>0204U</b>	Oncology (thyroid), mRNA, gene expression analysis of 593 genes (including BRAF, RAS, RET, PAX8, and NTRK) for sequence variants and rearrangements, utilizing fine needle aspirate, reported as detected or not detected	Investigational

<b>0205U</b>	Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements	Investigational
<b>0206U</b>	Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease	Investigational
<b>0207T</b>	Evacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral	Investigational
<b>0207U</b>	Neurology (Alzheimer disease); quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure)	Investigational
<b>0209U</b>	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities	Investigational
<b>0211U</b>	Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association	Investigational

<b>0216U</b>	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants	Investigational
<b>0217U</b>	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants	Investigational
<b>0218U</b>	Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or saliva, identification and characterization of genetic variants	Investigational
<b>0219U</b>	Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility	Investigational
<b>0220U</b>	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3	Investigational
<b>0223U</b>	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	Investigational

<b>0224U</b>	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), includes titer(s), when performed	Investigational
<b>0225U</b>	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected	Investigational
<b>0227U</b>	Drug assay, presumptive, 30 or more drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, includes sample validation	Investigational
<b>0228U</b>	Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer	Investigational
<b>0229U</b>	BCAT1 (Branched chain amino acid transaminase 1) or IKZF1 (IKAROS family zinc finger 1) (eg, colorectal cancer) promoter methylation analysis	Investigational
<b>0232T</b>	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed	Investigational
<b>0242U</b>	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 55-74 genes, interrogation for sequence variants, gene copy number amplifications, and gene rearrangements	Investigational

<b>0243U</b>	Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia	Investigational
<b>0244U</b>	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite instability, utilizing formalin-fixed paraffin-embedded tumor tissue	Investigational
<b>0247U</b>	Obstetrics (preterm birth), insulin-like growth factor-binding protein 4 (IBP4), sex hormone-binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth	Investigational
<b>0248U</b>	Oncology (brain), spheroid cell culture in a 3D microenvironment, 12 drug panel, tumor-response prediction for each drug	Investigational
<b>0249U</b>	Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection, with algorithmic analysis and interpretative report	Investigational
<b>0250U</b>	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden	Investigational

<b>0251U</b>	Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma	Investigational
<b>0252U</b>	Fetal aneuploidy short tandem-repeat comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploidy	Investigational
<b>0253T</b>	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, internal approach, into the suprachoroidal space	Investigational
<b>0253U</b>	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (eg, pre-receptive, receptive, post-receptive)	Investigational
<b>0255U</b>	Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score	Investigational
<b>0258U</b>	Autoimmune (psoriasis), mRNA, next-generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics	Investigational
<b>0259U</b>	Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myoinositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative	Investigational

<b>0260U</b>	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	Investigational
<b>0261U</b>	Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score	Investigational
<b>0262U</b>	Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffin-embedded (FFPE), algorithm reported as gene pathway activity score	Investigational
<b>0263T</b>	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest	Investigational
<b>0263U</b>	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon metabolites (ie, a-ketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (LC-MS/MS), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)	Investigational

<b>0264T</b>	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest	Investigational
<b>0264U</b>	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	Investigational
<b>0265T</b>	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy	Investigational
<b>0266T</b>	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	Investigational
<b>0266U</b>	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole-transcriptome and next-generation sequencing, blood, formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes	Investigational
<b>0267T</b>	Implantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	Investigational

<b>0267U</b>	Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing	Investigational
<b>0268T</b>	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	Investigational
<b>0269T</b>	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	Investigational
<b>0270T</b>	Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	Investigational
<b>0271T</b>	Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	Investigational
<b>0272T</b>	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day);	Investigational

<b>0273T</b>	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day); with programming	Investigational
<b>0274T</b>	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; cervical or thoracic	Investigational
<b>0275T</b>	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; lumbar	Investigational
<b>0278T</b>	Transcutaneous electrical modulation pain reprocessing (eg, scrambler therapy), each treatment session (includes placement of electrodes)	Investigational
<b>0279U</b>	Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen III binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen III binding	Investigational

<b>0280U</b>	Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen IV binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen IV binding	Investigational
<b>0281U</b>	Hematology (von Willebrand disease [VWD]), von Willebrand propeptide, enzyme-linked immunosorbent assays (ELISA), plasma, diagnostic report of von Willebrand factor (VWF) propeptide antigen level	Investigational
<b>0282U</b>	Red blood cell antigen typing, DNA, genotyping of 12 blood group system genes to predict 44 red blood cell antigen phenotypes	Investigational
<b>0283U</b>	von Willebrand factor (VWF), type 2B, platelet-binding evaluation, radioimmunoassay, plasma	Investigational
<b>0284U</b>	von Willebrand factor (VWF), type 2N, factor VIII and VWF binding evaluation, enzyme-linked immunosorbent assays (ELISA), plasma	Investigational
<b>0285U</b>	Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score	Investigational
<b>0288U</b>	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score	Investigational
<b>0289U</b>	Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score	Investigational

<b>0290U</b>	Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score	Investigational
<b>0291U</b>	Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score	Investigational
<b>0292U</b>	Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score	Investigational
<b>0293U</b>	Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score	Investigational
<b>0294U</b>	Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score	Investigational
<b>0295U</b>	Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a recurrence risk score	Investigational
<b>0296U</b>	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy	Investigational

<b>0297U</b>	Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification	Investigational
<b>0298U</b>	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification	Investigational
<b>0299U</b>	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification	Investigational
<b>0300U</b>	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification	Investigational
<b>0303U</b>	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic	Investigational
<b>0304U</b>	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic	Investigational

<b>0305U</b>	Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index	Investigational
<b>0306U</b>	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for future comparisons to evaluate for MRD	Investigational
<b>0307U</b>	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD	Investigational
<b>0308U</b>	Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for obstructive CAD	Investigational
<b>0309U</b>	Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event	Investigational
<b>0310U</b>	Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NT-proBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD	Investigational
<b>0311U</b>	Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility for each organisms identified	Investigational

<b>0312T</b>	Vagus nerve blocking therapy (morbid obesity); laparoscopic implantation of neurostimulator electrode array, anterior and posterior vagal trunks adjacent to esophagogastric junction (EGJ), with implantation of pulse generator, includes programming	Investigational
<b>0312U</b>	Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment	Investigational
<b>0313T</b>	Vagus nerve blocking therapy (morbid obesity); laparoscopic revision or replacement of vagal trunk neurostimulator electrode array, including connection to existing pulse generator	Investigational
<b>0313U</b>	Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia)	Investigational
<b>0314T</b>	Vagus nerve blocking therapy (morbid obesity); laparoscopic removal of vagal trunk neurostimulator electrode array and pulse generator	Investigational

<b>0314U</b>	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)	Investigational
<b>0315T</b>	Vagus nerve blocking therapy (morbid obesity); removal of pulse generator	Investigational
<b>0315U</b>	Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (ie, Class 1, Class 2A, Class 2B)	Investigational
<b>0316T</b>	Vagus nerve blocking therapy (morbid obesity); replacement of pulse generator	Investigational
<b>0316U</b>	Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine	Investigational
<b>0317T</b>	Vagus nerve blocking therapy (morbid obesity); neurostimulator pulse generator electronic analysis, includes reprogramming when performed	Investigational
<b>0317U</b>	Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm-generated evaluation reported as decreased or increased risk for lung cancer	Investigational
<b>0318U</b>	Pediatrics (congenital epigenetic disorders), whole genome methylation analysis by microarray for 50 or more genes, blood	Investigational
<b>0319U</b>	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection	Investigational

<b>0320U</b>	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using posttransplant peripheral blood, algorithm reported as a risk score for acute cellular rejection	Investigational
<b>0321U</b>	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique	Investigational
<b>0322U</b>	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD	Investigational
<b>0330T</b>	Tear film imaging, unilateral or bilateral, with interpretation and report	Investigational
<b>0332T</b>	Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; with tomographic SPECT	Investigational
<b>0335T</b>	Insertion of sinus tarsi implant	Investigational
<b>0338T</b>	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral	Investigational

<b>0339T</b>	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral	Investigational
<b>0397T</b>	Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure)	Investigational
<b>0421T</b>	Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed)	Investigational
<b>0424T</b>	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)	Investigational
<b>0425T</b>	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only	Investigational
<b>0426T</b>	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only	Investigational
<b>0427T</b>	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only	Investigational
<b>0428T</b>	Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only	Investigational

<b>0429T</b>	Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only	Investigational
<b>0430T</b>	Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead only	Investigational
<b>0431T</b>	Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only	Investigational
<b>0432T</b>	Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only	Investigational
<b>0433T</b>	Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only	Investigational
<b>0434T</b>	Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea	Investigational
<b>0435T</b>	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session	Investigational
<b>0436T</b>	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study	Investigational
<b>0441T</b>	Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve	Investigational
<b>0449T</b>	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; initial device	Investigational
<b>0450T</b>	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; each additional device (List separately in addition to code for primary procedure)	Investigational
<b>0506T</b>	Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report	Investigational

<b>0507T</b>	Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report	Investigational
<b>0508T</b>	Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia	Investigational
<b>0509T</b>	Electroretinography (ERG) with interpretation and report, pattern (PERG)	Investigational
<b>0510T</b>	Removal of sinus tarsi implant	Investigational
<b>0511T</b>	Removal and reinsertion of sinus tarsi implant	Investigational
<b>0512T</b>	Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; initial wound	Investigational
<b>0513T</b>	Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; each additional wound (List separately in addition to code for primary procedure)	Investigational
<b>0514T</b>	Intraoperative visual axis identification using patient fixation (List separately in addition to code for primary procedure)	Investigational
<b>0515T</b>	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])	Investigational
<b>0516T</b>	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only	Investigational

<b>0517T</b>	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only	Investigational
<b>0518T</b>	Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacin	Investigational
<b>0519T</b>	Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter)	Investigational
<b>0520T</b>	Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode	Investigational
<b>0521T</b>	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing	Investigational
<b>0522T</b>	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing	Investigational

<b>0523T</b>	Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention (List separately in addition to code for primary procedure)	Investigational
<b>0524T</b>	Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring	Investigational
<b>0525T</b>	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)	Investigational
<b>0526T</b>	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only	Investigational
<b>0527T</b>	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only	Investigational
<b>0528T</b>	Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report	Investigational

<b>0529T</b>	Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report	Investigational
<b>0530T</b>	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)	Investigational
<b>0531T</b>	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only	Investigational
<b>0532T</b>	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only	Investigational
<b>0533T</b>	Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report	Investigational
<b>0534T</b>	Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor	Investigational
<b>0535T</b>	Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration	Investigational
<b>0536T</b>	Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report	Investigational

<b>0541T</b>	Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learning-derived clinical scoring, and automated report generation, single study;	Investigational
<b>0542T</b>	Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learning-derived clinical scoring, and automated report generation, single study; interpretation and report	Investigational
<b>0543T</b>	Transapical mitral valve repair, including transthoracic echocardiography, when performed, with placement of artificial chordae tendineae	Investigational
<b>0545T</b>	Transcatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach	Investigational
<b>0546T</b>	Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report	Investigational
<b>0547T</b>	Bone-material quality testing by microindentation(s) of the tibia(s), with results reported as a score	Investigational
<b>0553T</b>	Percutaneous transcatheter placement of iliac arteriovenous anastomosis implant, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention	Investigational

<b>0554T</b>	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report	Investigational
<b>0555T</b>	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data	Investigational
<b>0556T</b>	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; assessment of bone strength and fracture risk and bone mineral density	Investigational
<b>0557T</b>	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; interpretation and report	Investigational
<b>0558T</b>	Computed tomography scan taken for the purpose of biomechanical computed tomography analysis	Investigational
<b>0559T</b>	Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure	Investigational
<b>0560T</b>	Anatomic model 3D-printed from image data set(s); each additional individually prepared and processed component of an anatomic structure (List separately in addition to code for primary procedure)	Investigational
<b>0561T</b>	Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide	Investigational

<b>0562T</b>	Anatomic guide 3D-printed and designed from image data set(s); each additional anatomic guide (List separately in addition to code for primary procedure)	Investigational
<b>0563T</b>	Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral	Investigational
<b>0564T</b>	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on percent of cytotoxicity observed, a minimum of 14 drugs or drug combinations	Investigational
<b>0565T</b>	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation	Investigational
<b>0566T</b>	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral	Investigational
<b>0567T</b>	Permanent fallopian tube occlusion with degradable biopolymer implant, transcervical approach, including transvaginal ultrasound	Investigational
<b>0568T</b>	Introduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach, including transvaginal ultrasound and pelvic ultrasound	Investigational
<b>0569T</b>	Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis	Investigational
<b>0570T</b>	Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure)	Investigational

<b>0581T</b>	Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral	Investigational
<b>0582T</b>	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance	Investigational
<b>0583T</b>	Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia	Investigational
<b>0587T</b>	Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	Investigational
<b>0588T</b>	Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	Investigational
<b>0589T</b>	Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters	Investigational

<b>0590T</b>	Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters	Investigational
<b>0594T</b>	Osteotomy, humerus, with insertion of an externally controlled intramedullary lengthening device, including intraoperative imaging, initial and subsequent alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device	Investigational
<b>0596T</b>	Temporary female intraurethral valve-pump (ie, voiding prosthesis); initial insertion, including urethral measurement	Investigational
<b>0597T</b>	Temporary female intraurethral valve-pump (ie, voiding prosthesis); replacement	Investigational
<b>0598T</b>	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (eg, lower extremity)	Investigational
<b>0599T</b>	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site (eg, upper extremity) (List separately in addition to code for primary procedure)	Investigational

<b>0602T</b>	Glomerular filtration rate (GFR) measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent	Investigational
<b>0603T</b>	Glomerular filtration rate (GFR) monitoring, transdermal, including sensor placement and administration of more than one dose of fluorescent pyrazine agent, each 24 hours	Investigational
<b>0604T</b>	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; initial device provision, set-up and patient education on use of equipment	Investigational
<b>0605T</b>	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; remote surveillance center technical support, data analyses and reports, with a minimum of 8 daily recordings, each 30 days	Investigational
<b>0606T</b>	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; review, interpretation and report by the prescribing physician or other qualified health care professional of remote surveillance center data analyses, each 30 days	Investigational
<b>0607T</b>	Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; set-up and patient education on use of equipment	Investigational

<b>0608T</b>	Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; analysis of data received and transmission of reports to the physician or other qualified health care professional	Investigational
<b>0609T</b>	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); acquisition of single voxel data, per disc, on biomarkers (ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs	Investigational
<b>0610T</b>	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis	Investigational
<b>0611T</b>	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing for algorithmic analysis of biomarker data for determination of relative chemical differences between discs	Investigational
<b>0612T</b>	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); interpretation and report	Investigational
<b>0613T</b>	Percutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist, when performed	Investigational

<b>0614T</b>	Removal and replacement of substernal implantable defibrillator pulse generator	Investigational
<b>0615T</b>	Eye-movement analysis without spatial calibration, with interpretation and report	Investigational
<b>0619T</b>	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed	Investigational
<b>0620T</b>	Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed	Investigational
<b>0621T</b>	Trabeculostomy ab interno by laser	Investigational
<b>0622T</b>	Trabeculostomy ab interno by laser; with use of ophthalmic endoscope	Investigational
<b>0623T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report	Investigational
<b>0624T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission	Investigational

<b>0625T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography	Investigational
<b>0626T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report	Investigational
<b>0627T</b>	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level	Investigational
<b>0628T</b>	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	Investigational
<b>0629T</b>	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level	Investigational
<b>0630T</b>	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	Investigational
<b>0631T</b>	Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity	Investigational

<b>0632T</b>	Percutaneous transcatheter ultrasound ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance	Investigational
<b>0633T</b>	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast material	Investigational
<b>0634T</b>	Computed tomography, breast, including 3D rendering, when performed, unilateral; with contrast material(s)	Investigational
<b>0635T</b>	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast, followed by contrast material(s)	Investigational
<b>0636T</b>	Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast material(s)	Investigational
<b>0637T</b>	Computed tomography, breast, including 3D rendering, when performed, bilateral; with contrast material(s)	Investigational
<b>0638T</b>	Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast, followed by contrast material(s)	Investigational
<b>0639T</b>	Wireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance, when performed	Investigational
<b>0640T</b>	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO <sub>2</sub> ]); image acquisition, interpretation and report, each flap or wound	Investigational

<b>0641T</b>	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO <sub>2</sub> ]); image acquisition only, each flap or wound	Investigational
<b>0642T</b>	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO <sub>2</sub> ]); interpretation and report only, each flap or wound	Investigational
<b>0643T</b>	Transcatheter left ventricular restoration device implantation including right and left heart catheterization and left ventriculography when performed, arterial approach	Investigational
<b>0646T</b>	Transcatheter tricuspid valve implantation (TTVI)/replacement with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed	Investigational
<b>0647T</b>	Insertion of gastrostomy tube, percutaneous, with magnetic gastropexy, under ultrasound guidance, image documentation and report	Investigational
<b>0648T</b>	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session; single organ	Investigational

<b>0649T</b>	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure); single organ (List separately in addition to code for primary procedure)	Investigational
<b>0651T</b>	Magnetically controlled capsule endoscopy, esophagus through stomach, including intraprocedural positioning of capsule, with interpretation and report	Investigational
<b>0652T</b>	Esophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	Investigational
<b>0653T</b>	Esophagogastroduodenoscopy, flexible, transnasal; with biopsy, single or multiple	Investigational
<b>0654T</b>	Esophagogastroduodenoscopy, flexible, transnasal; with insertion of intraluminal tube or catheter	Investigational
<b>0655T</b>	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging	Investigational
<b>0656T</b>	Vertebral body tethering, anterior; up to 7 vertebral segments	Investigational
<b>0657T</b>	Vertebral body tethering, anterior; 8 or more vertebral segments	Investigational
<b>0658T</b>	Electrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score	Investigational

<b>0659T</b>	Transcatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation	Investigational
<b>0660T</b>	Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach	Investigational
<b>0661T</b>	Removal and reimplantation of anterior segment intraocular nonbiodegradable drug-eluting implant	Investigational
<b>0664T</b>	Donor hysterectomy (including cold preservation); open, from cadaver donor	Investigational
<b>0665T</b>	Donor hysterectomy (including cold preservation); open, from living donor	Investigational
<b>0666T</b>	Donor hysterectomy (including cold preservation); laparoscopic or robotic, from living donor	Investigational
<b>0667T</b>	Donor hysterectomy (including cold preservation); recipient uterus allograft transplantation from cadaver or living donor	Investigational
<b>0668T</b>	Backbench standard preparation of cadaver or living donor uterine allograft prior to transplantation, including dissection and removal of surrounding soft tissues and preparation of uterine vein(s) and uterine artery(ies), as necessary	Investigational
<b>0669T</b>	Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; venous anastomosis, each	Investigational
<b>0670T</b>	Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; arterial anastomosis, each	Investigational

<b>0672T</b>	Endovaginal cryogen-cooled, monopolar radiofrequency remodeling of the tissues surrounding the female bladder neck and proximal urethra for urinary incontinence	Investigational
<b>0673T</b>	Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance	Investigational
<b>0674T</b>	Laparoscopic insertion of new or replacement of permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including an implantable pulse generator and diaphragmatic lead(s)	Investigational
<b>0675T</b>	Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first lead	Investigational
<b>0676T</b>	Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional lead (List separately in addition to code for primary procedure)	Investigational
<b>0677T</b>	Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first repositioned lead	Investigational

<b>0678T</b>	Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional repositioned lead (List separately in addition to code for primary procedure)	Investigational
<b>0679T</b>	Laparoscopic removal of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	Investigational
<b>0680T</b>	Insertion or replacement of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing lead(s)	Investigational
<b>0681T</b>	Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads	Investigational
<b>0682T</b>	Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads	Investigational

<b>0683T</b>	Programming device evaluation (in-person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	Investigational
<b>0684T</b>	Peri-procedural device evaluation (in-person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review, and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	Investigational
<b>0685T</b>	Interrogation device evaluation (in-person) with analysis, review and report by a physician or other qualified health care professional, including connection, recording and disconnection per patient encounter, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac funct	Investigational
<b>0686T</b>	Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant hepatocellular tissue, including image guidance	Investigational
<b>0687T</b>	Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session	Investigational
<b>0688T</b>	Treatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month	Investigational

<b>0689T</b>	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained without diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure)	Investigational
<b>0690T</b>	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained with diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)	Investigational
<b>0691T</b>	Automated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report	Investigational
<b>0693T</b>	Comprehensive full body computer-based markerless 3D kinematic and kinetic motion analysis and report	Investigational
<b>0694T</b>	3-dimensional volumetric imaging and reconstruction of breast or axillary lymph node tissue, each excised specimen, 3-dimensional automatic specimen reorientation, interpretation and report, real-time intraoperative	Investigational
<b>0695T</b>	Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of implant or replacement	Investigational

<b>0696T</b>	Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of follow-up interrogation or programming device evaluation	Investigational
<b>0697T</b>	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session; multiple organs	Investigational
<b>0698T</b>	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure); multiple organs (List separately in addition to code for primary procedure)	Investigational
<b>0700T</b>	Molecular fluorescent imaging of suspicious nevus; first lesion	Investigational
<b>0701T</b>	Molecular fluorescent imaging of suspicious nevus; each additional lesion (List separately in addition to code for primary procedure)	Investigational
<b>0702T</b>	Remote therapeutic monitoring of a standardized online digital cognitive behavioral therapy program ordered by a physician or other qualified health care professional; supply and technical support, per 30 days	Investigational

<b>0703T</b>	Remote therapeutic monitoring of a standardized online digital cognitive behavioral therapy program ordered by a physician or other qualified health care professional; management services by physician or other qualified health care professional, per calendar month	Investigational
<b>0704T</b>	Remote treatment of amblyopia using an eye tracking device; device supply with initial set-up and patient education on use of equipment	Investigational
<b>0705T</b>	Remote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days	Investigational
<b>0706T</b>	Remote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified health care professional, per calendar month	Investigational
<b>0707T</b>	Injection(s), bone substitute material (eg, calcium phosphate) into subchondral bone defect (ie, bone marrow lesion, bone bruise, stress injury, microtrabecular fracture), including imaging guidance and arthroscopic assistance for joint visualization	Investigational
<b>0708T</b>	Intradermal cancer immunotherapy; preparation and initial injection	Investigational
<b>0709T</b>	Intradermal cancer immunotherapy; each additional injection (List separately in addition to code for primary procedure)	Investigational

<b>0710T</b>	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; including data preparation and transmission, quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability, data review, interpretation and report	Investigational
<b>0711T</b>	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data preparation and transmission	Investigational
<b>0712T</b>	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability	Investigational
<b>0713T</b>	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data review, interpretation and report	Investigational
<b>20560</b>	Needle insertion(s) without injection(s); 1 or 2 muscle(s)	Investigational
<b>20561</b>	Needle insertion(s) without injection(s); 3 or more muscles	Investigational
<b>22526</b>	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level	Investigational
<b>22527</b>	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure)	Investigational

<b>22857</b>	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), single interspace, lumbar	Investigational
<b>22862</b>	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; lumbar	Investigational
<b>22867</b>	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; single level	Investigational
<b>22868</b>	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; second level (List separately in addition to code for primary procedure)	Investigational
<b>22869</b>	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; single level	Investigational
<b>22870</b>	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; second level (List separately in addition to code for primary procedure)	Investigational
<b>28890</b>	Extracorporeal shock wave, high energy, performed by a physician or other qualified health care professional, requiring anesthesia other than local, including ultrasound guidance, involving the plantar fascia	Investigational
<b>30468</b>	Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s)	Investigational

<b>31647</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with balloon occlusion, when performed, assessment of air leak, airway sizing, and insertion of bronchial valve(s), initial lobe	Investigational
<b>31648</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of bronchial valve(s), initial lobe	Investigational
<b>31649</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of bronchial valve(s), each additional lobe (List separately in addition to code for primary procedure)	Investigational
<b>31651</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with balloon occlusion, when performed, assessment of air leak, airway sizing, and insertion of bronchial valve(s), each additional lobe (List separately in addition to code for primary procedure[s])	Investigational
<b>31660</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 1 lobe	Investigational
<b>31661</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 2 or more lobes	Investigational
<b>33274</b>	Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed	Investigational
<b>33275</b>	Transcatheter removal of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography), when performed	Investigational

<b>33289</b>	Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed	Investigational
<b>33370</b>	Transcatheter placement and subsequent removal of cerebral embolic protection device(s), including arterial access, catheterization, imaging, and radiological supervision and interpretation, percutaneous (List separately in addition to code for primary procedure)	Investigational
<b>33548</b>	Surgical ventricular restoration procedure, includes prosthetic patch, when performed (eg, ventricular remodeling, SVR, SAVER, Dor procedures)	Investigational
<b>41512</b>	Tongue base suspension, permanent suture technique	Investigational
<b>42975</b>	Drug-induced sleep endoscopy, with dynamic evaluation of velum, pharynx, tongue base, and larynx for evaluation of sleep-disordered breathing, flexible, diagnostic	Investigational
<b>43206</b>	Esophagoscopy, flexible, transoral; with optical endomicroscopy	Investigational
<b>43252</b>	Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy	Investigational
<b>43284</b>	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed	Investigational
<b>43285</b>	Removal of esophageal sphincter augmentation device	Investigational
<b>43497</b>	Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM])	Investigational

<b>43647</b>	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum	Investigational
<b>43648</b>	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum	Investigational
<b>43881</b>	Implantation or replacement of gastric neurostimulator electrodes, antrum, open	Investigational
<b>43882</b>	Revision or removal of gastric neurostimulator electrodes, antrum, open	Investigational
<b>46707</b>	Repair of anorectal fistula with plug (eg, porcine small intestine submucosa [SIS])	Investigational
<b>47371</b>	Laparoscopy, surgical, ablation of 1 or more liver tumor(s); cryosurgical	Investigational
<b>47381</b>	Ablation, open, of 1 or more liver tumor(s); cryosurgical	Investigational
<b>47383</b>	Ablation, 1 or more liver tumor(s), percutaneous, cryoablation	Investigational
<b>53451</b>	Periurethral transperineal adjustable balloon continence device; bilateral insertion, including cystourethroscopy and imaging guidance	Investigational
<b>53452</b>	Periurethral transperineal adjustable balloon continence device; unilateral insertion, including cystourethroscopy and imaging guidance	Investigational
<b>53453</b>	Periurethral transperineal adjustable balloon continence device; removal, each balloon	Investigational
<b>53454</b>	Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of balloon(s) fluid volume	Investigational
<b>55706</b>	Biopsies, prostate, needle, transperineal, stereotactic template guided saturation sampling, including imaging guidance	Investigational
<b>55880</b>	Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance	Investigational

<b>58674</b>	Laparoscopy, surgical, ablation of uterine fibroid(s) including intraoperative ultrasound guidance and monitoring, radiofrequency	Investigational
<b>61736</b>	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; single trajectory for 1 simple lesion	Investigational
<b>61737</b>	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; multiple trajectories for multiple or complex lesion(s)	Investigational
<b>62263</b>	Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 2 or more days	Investigational
<b>62264</b>	Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 1 day	Investigational
<b>62287</b>	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar	Investigational
<b>62380</b>	Endoscopic decompression of spinal cord, nerve root(s), including laminotomy, partial facetectomy, foraminotomy, discectomy and/or excision of herniated intervertebral disc, 1 interspace, lumbar	Investigational

<b>64454</b>	Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed	Investigational
<b>64505</b>	Injection, anesthetic agent; sphenopalatine ganglion	Investigational
<b>64575</b>	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)	Investigational
<b>64585</b>	Revision or removal of peripheral neurostimulator electrode array	Investigational
<b>64624</b>	Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed	Investigational
<b>64625</b>	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)	Investigational
<b>64628</b>	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral	Investigational
<b>64629</b>	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure)	Investigational
<b>76120</b>	Cineradiography/videoradiography, except where specifically included	Investigational
<b>76125</b>	Cineradiography/videoradiography to complement routine examination (List separately in addition to code for primary procedure)	Investigational
<b>77085</b>	Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine), including vertebral fracture assessment	Investigational
<b>77086</b>	Vertebral fracture assessment via dual-energy X-ray absorptiometry (DXA)	Investigational
<b>78835</b>	Radiopharmaceutical quantification measurement(s) single area (List separately in addition to code for primary procedure)	Investigational

<b>81277</b>	Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities	Investigational
<b>81514</b>	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L. crispatus and L. jensenii), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and/or Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata, Candida krusei, when reported	Investigational
<b>81518</b>	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy	Investigational
<b>81539</b>	Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score	Investigational
<b>81560</b>	Transplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score	Investigational

<b>82107</b>	Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio)	Investigational
<b>82172</b>	Apolipoprotein, each	Investigational
<b>82523</b>	Collagen cross links, any method	Investigational
<b>82610</b>	Cystatin C	Investigational
<b>82664</b>	Electrophoretic technique, not elsewhere specified	Investigational
<b>83006</b>	Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)	Investigational
<b>83695</b>	Lipoprotein (a)	Investigational
<b>83721</b>	Lipoprotein, direct measurement; LDL cholesterol	Investigational
<b>83722</b>	Lipoprotein, direct measurement; small dense LDL cholesterol	Investigational
<b>83880</b>	Natriuretic peptide	Investigational
<b>83937</b>	Osteocalcin (bone g1a protein)	Investigational
<b>83987</b>	pH; exhaled breath condensate	Investigational
<b>84080</b>	Phosphatase, alkaline; isoenzymes	Investigational
<b>84181</b>	Protein; Western Blot, with interpretation and report, blood or other body fluid	Investigational
<b>85384</b>	Fibrinogen; activity	Investigational
<b>85385</b>	Fibrinogen; antigen	Investigational
<b>86305</b>	Human epididymis protein 4 (HE4)	Investigational
<b>86352</b>	Cellular function assay involving stimulation (eg, mitogen or antigen) and detection of biomarker (eg, ATP)	Investigational
<b>87426</b>	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])	Investigational
<b>88375</b>	Optical endomicroscopic image(s), interpretation and report, real-time or referred, each endoscopic session	Investigational
<b>90626</b>	Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use	Investigational

<b>90627</b>	Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use	Investigational
<b>90671</b>	Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use	Investigational
<b>90758</b>	Zaire ebolavirus vaccine, live, for intramuscular use	Investigational
<b>90759</b>	Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use	Investigational
<b>91111</b>	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus with interpretation and report	Investigational
<b>92145</b>	Corneal hysteresis determination, by air impulse stimulation, unilateral or bilateral, with interpretation and report	Investigational
<b>92548</b>	Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report;	Investigational
<b>92549</b>	Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)	Investigational
<b>92572</b>	Staggered spondaic word test	Investigational
<b>92576</b>	Synthetic sentence identification test	Investigational
<b>93050</b>	Arterial pressure waveform analysis for assessment of central arterial pressures, includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive	Investigational

<b>93264</b>	Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional	Investigational
<b>93356</b>	Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging)	Investigational
<b>93701</b>	Bioimpedance-derived physiologic cardiovascular analysis	Investigational
<b>95012</b>	Nitric oxide expired gas determination	Investigational
<b>95803</b>	Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)	Investigational
<b>95905</b>	Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and latency/velocity study, each limb, includes F-wave study when performed, with interpretation and report	Investigational
<b>95957</b>	Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis)	Investigational

<b>95976</b>	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional	Investigational
<b>95977</b>	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional	Investigational
<b>96000</b>	Comprehensive computer-based motion analysis by video-taping and 3D kinematics;	Investigational
<b>96001</b>	Comprehensive computer-based motion analysis by video-taping and 3D kinematics; with dynamic plantar pressure measurements during walking	Investigational
<b>96002</b>	Dynamic surface electromyography, during walking or other functional activities, 1-12 muscles	Investigational

<b>96003</b>	Dynamic fine wire electromyography, during walking or other functional activities, 1 muscle	Investigational
<b>96004</b>	Review and interpretation by physician or other qualified health care professional of comprehensive computer-based motion analysis, dynamic plantar pressure measurements, dynamic surface electromyography during walking or other functional activities, and dynamic fine wire electromyography, with written report	Investigational
<b>97033</b>	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes	Investigational
<b>97533</b>	Sensory integrative techniques to enhance sensory processing and promote adaptive responses to environmental demands, direct (one-on-one) patient contact, each 15 minutes	Investigational
<b>97610</b>	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day	Investigational
<b>97799</b>	Unlisted physical medicine/rehabilitation service or procedure	Investigational